Hong Kong Stocks on the Move: Innovent Biologics (01801) Rises Over 2% as Partner Ollin Set to Be Acquired by Johnson & Johnson; Core Phase III Asset IBI/OLN324 to Join J&J Pipeline

Stock News10:56

According to Zhitong Finance APP, Innovent Biologics (01801) rose over 2%, up 1.68% as of press time to HK$84.9, with turnover of HK$255 million.

On the news front, Johnson & Johnson recently announced the acquisition of Ollin Biosciences for US$2.2 billion in upfront payment, plus up to approximately US$1.125 billion in regulatory and commercial milestone payments, bringing the total transaction value to as much as US$3.325 billion.

UBS noted that Innovent Biologics' partner Ollin will be acquired by Johnson & Johnson, and the core Phase III asset IBI/OLN324 (Ang2/VEGF) will be incorporated into Johnson & Johnson's pipeline. UBS holds a positive view on this.

UBS believes the deal affirms Innovent Biologics' strength in ophthalmology R&D, including the US$2.2 billion upfront payment and up to US$1.125 billion in milestone payments. The Phase 1b clinical data for IBI/OLN324 in wAMD/DME is positive relative to faricimab. Blackstone will pay Johnson & Johnson US$750 million to fully fund the Phase III clinical trial of OLN324, in exchange for certain milestones and single-digit royalties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment